MedTrace Logo

OC000459 Dose Finding Study in Hay Fever Sufferers.

NCT00697281 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-02-24

No results posted yet for this study

Summary

The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis

Conditions

  • Allergic Rhinitis

Interventions

DRUG

OC000459

Tablets twice daily for 8 days Dose level 1

DRUG

OC000459

Tablets twice daily for 8 days Dose level 2

DRUG

OC000459

Tablets twice daily for 8 days Dose level 3

DRUG

OC000459

Tablets twice daily for 8 days Dose level 4

DRUG

Placebo

Tablets twice daily for 8 days Dose level 5

Sponsors & Collaborators

  • Oxagen Ltd

    lead INDUSTRY

Principal Investigators

  • Univ Prof. Dr. Friedrich Horak, MD · Allergie Zentrum Wien West

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697281 on ClinicalTrials.gov